News Image

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Provided By GlobeNewswire

Last update: Mar 17, 2025

PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the execution of another disciplined step in its financial strategy through the amendment of the Company’s global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company.

Read more at globenewswire.com

NANOBIOTIX SA - ADR

NASDAQ:NBTX (6/11/2025, 3:44:00 PM)

5.08

+0.23 (+4.74%)



Find more stocks in the Stock Screener

Follow ChartMill for more